Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) Other Operating Expenses (2020 - 2023)

Goldenwell Biotech (GWLL) has disclosed Other Operating Expenses for 4 consecutive years, with -$1.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Other Operating Expenses changed N/A year-over-year to -$1.0, compared with a TTM value of -$1.0 through Sep 2025, changed N/A, and an annual FY2022 reading of -$1.9 million, down 662.16% over the prior year.
  • Other Operating Expenses was -$1.0 for Q2 2025 at Goldenwell Biotech, up from -$61539.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at -$1.0 in Q2 2025 and bottomed at -$110750.0 in Q4 2021.
  • Average Other Operating Expenses over 3 years is -$63914.0, with a median of -$65086.5 recorded in 2023.
  • Peak annual rise in Other Operating Expenses hit 875.21% in 2021, while the deepest fall reached 875.21% in 2021.
  • Year by year, Other Operating Expenses stood at -$110750.0 in 2021, then skyrocketed by 44.43% to -$61539.0 in 2023, then soared by 100.0% to -$1.0 in 2025.
  • Business Quant data shows Other Operating Expenses for GWLL at -$1.0 in Q2 2025, -$61539.0 in Q3 2023, and -$68634.0 in Q1 2023.